The pharmaceutical company Bristol-Myers Squibb Australia (BMS), makers of Abatacept (Orencia®) have notified the Therapeutic Goods Administration of Australia (TGA) of anticipated shortages of both the 125mg Orencia (abatacept) ClickJect (autoinjector) and pre-filled syringe.
BMS expects a supply chain problem starting in June 2024, with supply issues being estimated for a period of several months. This is a global supply chain issue, and Australia is not the only country that is affected.
Arthritis Australia and the Australian Rheumatology Association (ARA) have recommended for those affected by the shortage to contact their treating rheumatologist or clinical immunologist for further guidance.
